Radiopharm Theranostics: The tip of the spear in cancer fighting technologies!
Listen to ASX-listed Radiopharm Theranostics Exec Chairman Paul Hopper talk to Matt Birney on the Bulls N’ Bears Report about Radiopharm’s $150m ASX listing that will develop a range of cancer fighting technologies based on “radiopharmaceuticals”.